Table 1

Percentage of patients with Crohn’s disease or ulcerative colitis with prescriptions of biologics or corticosteroids* (with and without biologics), overall and by age, sex, race and ethnicity, and number of comorbidities, 2019 IQVIA

Patient characteristicCrohn’s diseaseUlcerative colitis
%Biologics†Corticosteroids‡ with biologicsCorticosteroids‡ without biologics%Biologics†Corticosteroids‡ with biologicsCorticosteroids‡ without biologics
%
(95% CI)		P value%
(95% CI)		P value%
(95% CI)		P value%
(95% CI)		P value%
(95% CI)		P value%
(95% CI)		P value
OverallN=52, 89230.3
(29.9 to 30.7)		—11.0
(10.7 to 11.3)		—17.2
(16.9 to 17.5)		—N=52 28013.6
(13.4 to 13.9)		—5.9
(5.7 to 6.1)		—20.4
(20.0 to 20.7)		—
Age (years)
 <182.841.3
(38.7 to 43.8)		0.00116.8
(14.9 to 18.7)		<0.00113.0
(11.3 to 14.8)		0.0041.422.3
(19.3 to 25.3)		0.00312.5
(10.1 to 14.9)		<0.00120.1
(17.2 to 23.0)		0.89
 18–59 (ref)59.637.1
(36.6 to 37.6)		—13.6
(13.2 to 13.9)		—15.9
(15.4 to 16.3)		—53.418.0
(17.5 to 18.4)		—7.9
(7.6 to 8.3)		—20.3
(19.9 to 20.8)		—
 ≥6037.618.8
(18.3 to 19.3)		<0.0016.6
(6.2 to 6.9)		<0.00119.6
(19.0 to 20.1)		<0.00145.28.3
(7.9 to 8.6)		<0.0013.3
(3.1 to 3.6)		<0.00120.4
(19.9 to 20.9)		0.89
Sex
 Female (ref)58.129.3
(28.7 to 29.8)		—11.0
(10.7 to 11.4)		—17.9
(17.5 to 18.3)		—55.912.6
(12.2 to 13.0)		—5.5
(5.2 to 5.8)		—20.7
(20.2 to 21.1)		—
 Male41.931.8
(31.2 to 32.4)		<0.00111.0
(10.6 to 11.4)		0.8816.2
(15.7 to 16.6)		<0.00144.115.0
(14.5 to 15.5)		<0.0016.5
(6.1 to 6.8)		<0.00119.9
(19.4 to 20.5)		0.04
Race and ethnicity
 Non-Hispanic white (ref)77.730.8
(30.3 to 31.2)		—11.3
(11.0 to 11.6)		—17.4
(17.1 to 17.8)		—77.113.8
(13.5 to 14.1)		—6.0
(5.8 to 6.2)		—20.6
(20.2 to 21.0)		—
 Non-Hispanic black5.832.9
(31.2 to 34.6)		0.0111.9
(10.8 to 13.1)		0.3017.5
(16.1 to 18.8)		0.944.714.5
(13.1 to 15.9)		0.346.3
(5.3 to 7.2)		0.5719.9
(18.3 to 21.5)		0.41
 Other§2.029.4
(26.7 to 32.2)		0.3612.4
(10.4 to 14.4)		0.3018.7
(16.3 to 21.1)		0.292.615.1
(13.2 to 17.0)		0.167.3
(5.9 to 8.7)		0.0521.5
(19.3 to 23.7)		0.43
 Unknown14.627.1
(26.1 to 28.1)		<0.0018.8
(8.1 to 9.4)		<0.00115.4
(14.6 to 16.2)		<0.00115.712.4
(11.7 to 13.1)		<0.0015.3
(4.8 to 5.7)		0.0119.0
(18.2 to 19.9)		0.001
Number of comorbidities¶
 0 (ref)69.333.2
(32.7 to 33.7)		—11.7
(11.4 to 12.1)		—15.1
(14.8 to 15.5)		—69.915.0
(14.6 to 15.3)		—6.5
(6.2 to 6.7)		—19.0
(18.6 to 19.4)		—
 122.625.8
(25.0 to 26.6)		<0.00110.1
(9.5 to 10.6)		<0.00120.0
(19.3 to 20.7)		<0.00122.211.4
(10.9 to 12.0)		<0.0015.0
(4.6 to 5.4)		<0.00121.8
(21.0 to 22.5)		<0.001
 26.119.5
(18.1 to 20.9)		<0.0017.4
(6.5 to 8.3)		<0.00126.1
(24.6 to 27.6)		<0.0015.98.9
(7.9 to 9.8)		<0.0014.0
(3.3 to 4.7)		<0.00126.9
(25.3 to 28.4)		<0.001
 ≥32.013.8
(11.7 to 15.9)		<0.0017.3
(5.7 to 8.8)		<0.00129.5
(26.7 to 32.3)		<0.0012.06.5
(5.0 to 8.0)		<0.0013.3
(2.2 to 4.4)		<0.00132.6
(29.7 to 35.5)		<0.001

  • *With or without a biologic prescription within the same calendar year. The denominators are all patients with CD or UC.

  • †Including adalimumab, infliximab, certolizumab, golimumab, vedolizumab, natalizumab, and ustekinumab.

  • ‡Including prednisone, prednisolone, methylprednisolone, hydrocortisone, and budesonide.

  • §Others include Hispanics, non-Hispanic Asians, and other racial/ethnical groups.

  • ¶Comorbidities include cardiovascular disease (acute myocardial infarction, heart failure, and stroke), diabetes, depression, chronic obstructive pulmonary disease, obesity, chronic kidney disease.

  • ref, referent group.